research use only
Cat.No.S9702
| Related Targets | Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES |
|---|---|
| Other Mineralocorticoid Receptor Inhibitors | Apararenone Canrenone Esaxerenone (CS-3150) |
|
In vitro |
DMSO
: 76 mg/mL
(200.83 mM)
Ethanol : 10 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 378.42 | Formula | C21H22N4O3 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1050477-31-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | FIN, BAY 94-8862 | Smiles | CCOC1=NC=C(C)C2=C1C(C3=CC=C(C=C3OC)C#N)C(=C(C)N2)C(N)=O | ||
| Targets/IC50/Ki |
MR
(Cell-free assay) 18 nM
|
|---|---|
| In vitro |
In vitro, Finererone dose-dependently reduces aldosterone-induced smooth muscle cell (SMC) proliferation and prevents aldosteroneinduced endothelial cell (EC) apoptosis. This compound significantly reduces apoptosis of ECs and simultaneously attenuates SMC proliferation, resulting in accelerated endothelial healing and reduced neointima formation of the injured vessels. |
| In vivo |
Finerenone improves endothelial dysfunction through an enhancement in NO bioavailability and a decrease in superoxide anion levels due to an upregulation in SOD activity. This is associated with an increase in renal SOD activity and a reduction of albuminuria. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06330974 | Not yet recruiting | Asthma|Asthma in Children|Allergy|Rhinitis Allergic|Atopic Dermatitis|Allergen Immunotherapy |
Tampere University|Professor Lauri Lehtimäki|Professor Mika Mäkelä|Professor Sanna Toppila-Salmi|Professor Ilkka Junttila |
October 2024 | -- |
| NCT06402760 | Not yet recruiting | Psoriasis|Diabetes |
Shanghai Yueyang Integrated Medicine Hospital|Shanghai Hongkou District Center for Disease Control And Prevention |
July 1 2024 | Early Phase 1 |
| NCT06359418 | Not yet recruiting | Obesity|Pre-diabetes |
Guang''anmen Hospital of China Academy of Chinese Medical Sciences|Hubei Hospital of Traditional Chinese Medicine|The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine|Dongfang Hospital Beijing University of Chinese Medicine|Guangdong Provincial Hospital of Traditional Chinese Medicine|Heilongjiang Academy of traditional Chinese Medicine |
April 10 2024 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.